Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Queensland Health

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,103,515

« Back to Dashboard

Summary for Patent: 6,103,515

Title: Production of polypeptides by use of novel protease deficient yeast strains
Abstract:A novel process for the production of heterologous proteins including the use of certain transformed protease deficient yeast strains is provided. The invention concerns also said transformed yeast strains and methods for the production thereof.
Inventor(s): Treichler; Hansjorg (Kanerkinden, CH), Takabayashi; Kenji (Basel, CH), Wolf; Dieter Heinrich (Gundelfingen, DE), Heim; Jutta (Ramlinsburg, CH)
Assignee: Novartis Corporation (New York, NY) UCP Gen-Pharma AG (Kirchberg, CH)
Application Number:07/895,581
Patent Claim Types:
see list of patent claims
Compound; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,103,515

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8810524May 04, 1988
United Kingdom8812627May 27, 1988
United Kingdom8907110Mar 29, 1989

International Patent Family for Patent: 6,103,515

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria124086► Subscribe
Australia3382889► Subscribe
Australia614121► Subscribe
Canada1340016► Subscribe
German Democratic Republic283839► Subscribe
Germany68923123► Subscribe
Denmark175701► Subscribe
Denmark217589► Subscribe
European Patent Office0341215► Subscribe
Spain2072918► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
US Army
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus